Awaiting the outcome of the Patient Capital Review with an eagerness that borders on, well, impatience, Ian Battersby wonders how financial advisers will be expected to embrace whatever new rules emerge
The results of the Patient Capital Review are eagerly anticipated by tax-advantaged product providers, advisers and investors alike but, at the present time, there is very little clarity about what might...
Has entered world of face-to-face advice
Four key risks
37 counts of fraud
E-learning an option
The end of Goldilocks?